Secondary progressive multiple sclerosis

Researchers are testing a one-time CAR-T cell therapy called C-CAR168 in adults with progressive multiple sclerosis that has not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to target two proteins, and is given as a single intravenou…

This trial is testing an experimental therapy called CTA313, which uses engineered immune cells (CAR T cells) to potentially reset the immune system in people with active autoimmune diseases. The study will include adults aged 18 to 75 with systemic lupus erythematosus, progressi…

This study tests an experimental drug called remibrutinib in 20 people with relapsing or progressive multiple sclerosis (MS). Participants take the drug twice daily for 2 years and undergo powerful 7T MRI scans to measure changes in brain volume, lesions, and tissue health. The g…

This phase 2 trial tests whether indapamide, a common diuretic, can slow the worsening of walking ability in people with progressive multiple sclerosis (MS). Participants take one tablet daily for 12 months, with walking speed measured regularly. The study aims to see if the drug…

This early-stage trial tests a new treatment for multiple sclerosis (MS) that combines a drug called ofatumumab with NK042, a therapy made from immune cells donated by healthy people. The study will include 20 adults with different types of MS and will primarily check for safety …

This study tests a six-month personalized telenursing program for 110 adults with multiple sclerosis. Participants receive monthly educational videos and nurse-led video calls to help them better understand their health and navigate the healthcare system. The goal is to improve h…

This study tests whether breathing low-oxygen air for short periods right before walking training helps people with multiple sclerosis walk better and farther. Thirty-five participants will receive either the low-oxygen breathing or a sham (placebo) version, followed by treadmill…

This early-stage trial tests whether a combination of two drugs, dasatinib and quercetin, can safely remove aged, damaged cells that may contribute to inflammation and nerve damage in people with secondary progressive multiple sclerosis (MS). The study enrolls 30 adults aged 50-8…

This study looks at whether the time of day you eat can affect brain health in people with multiple sclerosis. Twenty-two adults with MS will follow a daily eating schedule for a set period. Researchers will measure markers of nerve health and inflammation in the blood. A small g…